Faldaprevir for treating genotype 1 chronic hepatitis C
Status Suspended
Process STA pre-2018
Referral date 01 February 2014
Topic area
  • Digestive system
  • Infectious diseases

Provisional Schedule

Closing date for invited submissions / evidence submission: TBC
1st appraisal committee meeting: TBC

Project Team

Communications manager: TBC
Executive Lead: TBC
Project manager:

Jeremy Powell

Technical Lead: TBC


Key events during the development of the guidance:

Date Update
09 July 2014 The manufacturer of faldaprevir, Boehringer Ingelheim, has informed us that it has decided not to proceed with the development of faldaprevir for treating hepatitis C. Boehringer Ingelheim has re-evaluated its strategy in hepatitis C, and considers that there are now several new treatment options available for patients and that there is no longer an unmet medical need that would be filled with its faldaprevir interferon-based regimen

For further information on how we develop guidance, please see our page about NICE technology appraisal guidance